Soleno Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Soleno Therapeutics
SLNO Stock  USD 40.55  1.99  5.16%   
Soleno Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Soleno Therapeutics' valuation are provided below:
Gross Profit
96.8 M
Profit Margin
(0.80)
Market Capitalization
2.1 B
Enterprise Value Revenue
17.5329
Revenue
98.7 M
We have found one hundred twenty available fundamental trend indicators for Soleno Therapeutics, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Soleno Therapeutics' current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 1st of February 2026, Market Cap is likely to grow to about 1.7 B. Also, Enterprise Value is likely to grow to about 1.7 B

Soleno Therapeutics Total Revenue

(1.55 Billion)

Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 197.5 K or Selling General Administrative of 127.8 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.85 or Days Sales Outstanding of 53.01. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Soleno Stock
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

Soleno Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets399.6 M380.6 M92.4 M
Slightly volatile
Short and Long Term Debt Total63.8 M60.7 M13.4 M
Slightly volatile
Other Current Liabilities11.3 M10.7 M3.6 M
Slightly volatile
Total Current Liabilities22.6 M21.6 M9.5 M
Slightly volatile
Other Liabilities9.1 M10.2 M7.7 M
Slightly volatile
Property Plant And Equipment Net3.6 M3.4 M724.2 K
Slightly volatile
Accounts Payable10.7 M10.2 M2.8 M
Slightly volatile
Cash106.2 M101.1 M37.3 M
Slightly volatile
Non Current Assets Total44.8 M42.6 M13.7 M
Slightly volatile
Non Currrent Assets Other71 K74.7 K1.2 M
Very volatile
Cash And Short Term Investments351.9 M335.2 M77.6 M
Slightly volatile
Net Receivables104.6 K57.6 K101.3 K
Slightly volatile
Common Stock Total Equity96.6 K92 K42.6 K
Slightly volatile
Common Stock Shares Outstanding48.5 M46.2 M10.2 M
Slightly volatile
Liabilities And Stockholders Equity399.6 M380.6 M92.4 M
Slightly volatile
Non Current Liabilities Total81 M77.2 M25.1 M
Slightly volatile
Other Current Assets3 M2.8 M981.9 K
Slightly volatile
Other Stockholder Equity841.6 M801.5 M257.4 M
Slightly volatile
Total Liabilities103.7 M98.7 M34.6 M
Slightly volatile
Property Plant And Equipment Gross3.7 M3.5 M747.2 K
Slightly volatile
Total Current Assets354.9 M338 M78.7 M
Slightly volatile
Short Term Debt449.7 K473.4 K3.1 M
Slightly volatile
Common Stock32.2 K52.9 K27.5 K
Slightly volatile
Property Plant Equipment110.1 K180.6 K112.7 K
Slightly volatile
Capital Surpluse149.3 M262.1 M148 M
Slightly volatile
Deferred Long Term Liabilities460.8 K485.1 K6.8 M
Slightly volatile
Short and Long Term Debt81.2 K91.4 K99.7 K
Slightly volatile
Warrants6.144.55.5082
Very volatile
Non Current Liabilities Other17.9 M17 M6.3 M
Slightly volatile
Net Invested Capital356.1 M339.2 M87 M
Slightly volatile
Net Working Capital332.2 M316.4 M77.5 M
Slightly volatile
Capital Stock36.9 K41.4 K38.7 K
Pretty Stable
Long Term Debt Total6.4 K7.2 K7.9 K
Slightly volatile
Capital Lease Obligations3.6 M3.4 M839.4 K
Slightly volatile

Soleno Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M2.3 M1.2 M
Slightly volatile
Selling General Administrative127.8 M121.7 M25.8 M
Slightly volatile
Other Operating Expenses226.6 M215.8 M50.2 M
Slightly volatile
Research Development94.9 M90.4 M23.4 M
Slightly volatile
Total Operating Expenses226.6 M215.8 M49.8 M
Slightly volatile
Selling And Marketing Expenses1.2 M2.3 M1.3 M
Slightly volatile
Preferred Stock And Other Adjustments3 M3.3 M3.6 M
Slightly volatile
Reconciled Depreciation2.1 M2.3 M1.8 M
Slightly volatile
Interest Income14.6 M13.9 M2.7 M
Slightly volatile

Soleno Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation120.7 M115 M20.8 M
Slightly volatile
Begin Period Cash Flow204.9 M195.1 M43.4 M
Slightly volatile
Depreciation1.3 M2.3 M1.1 M
Slightly volatile
End Period Cash Flow106.2 M101.1 M37.3 M
Slightly volatile
Issuance Of Capital Stock179.9 M171.3 M45.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Days Sales Outstanding53.0130.1944.2354
Very volatile
Average Payables351.9 K667 K572.1 K
Slightly volatile
Capex To Depreciation0.120.130.2884
Pretty Stable
Inventory Turnover1.172.061.6259
Slightly volatile
Days Of Inventory On Hand174184307
Slightly volatile
Payables Turnover0.690.721.0738
Pretty Stable
Average Inventory514.7 K379.7 K457.4 K
Slightly volatile
Cash Per Share7.938.3461.5927
Slightly volatile
Days Payables Outstanding549522458
Pretty Stable
Income Quality0.560.350.65
Pretty Stable
Intangibles To Total Assets0.02250.02360.2328
Slightly volatile
Current Ratio14.8114.116.4396
Slightly volatile
Receivables Turnover12.2512.5112.2271
Slightly volatile
Capex Per Share0.00590.00620.2912
Slightly volatile
Average Receivables101.7 K76.7 K90.1 K
Slightly volatile
Interest Debt Per Share1.441.52202
Slightly volatile
Debt To Assets0.170.181.3345
Slightly volatile
Operating Cycle248174216
Very volatile
Days Of Payables Outstanding549522458
Pretty Stable
Ebt Per Ebit1.611.081.4856
Slightly volatile
Quick Ratio14.8114.116.4017
Slightly volatile
Net Income Per E B T0.871.011.054
Pretty Stable
Cash Ratio4.064.224.3868
Slightly volatile
Days Of Inventory Outstanding174184307
Slightly volatile
Days Of Sales Outstanding53.0130.1944.2354
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0178
Slightly volatile
Debt Ratio0.170.181.3345
Slightly volatile

Soleno Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B520.7 M
Slightly volatile
Enterprise Value1.7 B1.6 B501.1 M
Slightly volatile

Soleno Fundamental Market Drivers

Forward Price Earnings7.9051
Cash And Short Term Investments291.4 M

Soleno Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Soleno Therapeutics Financial Statements

Soleno Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.8 M5 M
Cost Of Revenue1.8 M1.6 M
Revenue Per Share-3 K-2.8 K
Ebit Per Revenue 0.01  0.01 

Pair Trading with Soleno Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Soleno Stock

  0.66EVGN EvogenePairCorr
  0.8IMNN Imunon IncPairCorr
  0.84LYRA Lyra TherapeuticsPairCorr
  0.8MBIO Mustang BioPairCorr

Moving against Soleno Stock

  0.54MRKR Marker TherapeuticsPairCorr
  0.52CING CingulatePairCorr
  0.5MOLN Molecular PartnersPairCorr
  0.49ARWR Arrowhead PharmaceuticalsPairCorr
  0.47AEON AEON BiopharmaPairCorr
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
How To Invest In Soleno
Details
Is Soleno Stock a good investment?
Details
What is Soleno Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.75)
Revenue Per Share
2.034
Return On Assets
(0.12)
Return On Equity
(0.21)
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value—what Soleno Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY